Ivermectin (dihydroavermectin B1) is an antiparasitic agent of the avermectin class. Ivermectin has structural similarities to the macrolide antibiotics but lacks antibacterial activity. Avermectins are produced naturally by the actinomycete Streptomycetes avermetilis. Ivermectin lotion is used topically to treat Pediculosis capitis (head lice). Ivermectin cream is used topically for the treatment of inflammatory lesions of rosacea. Oral ivermectin is used in treating infections due to Onchocerca volvulus (onchocerciasis) or Strongyloides stercoralis (strongyloidiasis). Ivermectin is only active against the tissue microfilariae of Onchocerca volvulus and the intestinal stage of Strongyloides stercoralis; ivermectin has no activity against adult Onchocerca volvulus. Although not FDA-approved for infections due to Sarcoptes scabiei (scabies), crusted (Norwegian) scabies, or superinfected scabies, ivermectin has been used successfully to treat these conditions. Ivermectin is effective against the circulating microfilariae of Wuchereria bancrofti (responsible for Bancroft's filariasis) and other major filarial diseases (i.e., Loa loa). However, ivermectin is not effective against Mansonella perstans. Ivermectin has also demonstrated promise for the treatment of nematodes such as cutaneous larva currens and localized and disseminated cutaneous larva migrans. Ivermectin is recommend by The World Health Organization (WHO) for treating onchocerciasis (river blindness) and lymphatic filariasis (Bancroft's filariasis). Resistance to ivermectin has not been reported. Ivermectin oral tablets were FDA-approved in November 1996. Ivermectin lotion was approved in February 2012. Ivermectin cream was approved in December 2014.
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Oral Solid Formulations
-Administer ivermectin tablets on an empty stomach with water.
-Ivermectin lotion is administered topically for head lice. Avoid contact with eyes, mouth, or any mucus membrane. Do not ingest.
-Scalp and hair should be dry prior to application.
-Apply a sufficient amount to thoroughly cover scalp and hair (up to the full contents of 1 tube).
-Leave on for 10 minutes, and then rinse with only water.
-Wash hands after use.
-Wait 24 hours before applying shampoo to hair and scalp after use.
-The tube is for single use only; discard any unused portion.
-For proper treatment of pediculosis, wash in hot water or dry clean all recently worn clothing, hats, used bedding and towels, and wash personal care items such as combs, brushes, and hair clips in hot water.
-Ivermectin cream is administered topically for rosacea. Avoid contact with eyes and lips.
-It is not for oral, ophthalmic, or intravaginal use.
-Apply to the affected areas of the face.
Worsening of bronchial asthma has been reported with systemic ivermectin use in post-marketing experience.
Ivermectin is generally well tolerated, particularly with single-dose use. Compared to other antiparasitics used for similar indications, fewer adverse effects and better compliance are usually seen with ivermectin. Adverse events are typically not dose-related. The side effects reported in clinical experience have varied according to the underlying disease or indication for treatment. In patients being treated for onchocerciasis, the most common adverse reactions were related to allergic and inflammatory responses to the death of the microfilariae (the Mazzotti reaction). Especially in severe onchocerciasis disease, ivermectin may be administered with a corticosteroid, an antihistamine, or another antiinflammatory agent to minimize these reactions. Patients with hyperreactive onchodermatitis (sowda) may be more likely than others to experience severe adverse reactions, especially edema and aggravation of onchodermatitis. Mazzotti-type and ophthalmologic reactions associated with the treatment of onchocerciasis or the disease itself would not be expected in patients with strongyloidiasis being treated with ivermectin.
In patients being treated for onchocerciasis with ivermectin, adverse reactions related to allergic and inflammatory responses to the death of the microfilariae (the Mazzotti reaction) include arthralgia or synovitis (9.3%) as well as axillary, cervical, inguinal, and other lymphadenopathy (3% to 12.6%) and tenderness (1.2% to 13.9%).
In patients being treated for onchocerciasis with systemic ivermectin, adverse reactions related to allergic and inflammatory responses to the death of the microfilariae (the Mazzotti reaction) include pruritus (27.5%) and other skin involvement that may manifest as angioedema (1.2%), peripheral edema (3.2%), rashes including maculopapular rash, pustular rash, or urticaria (22.7%). Adverse reactions associated with strongyloidiasis treatment include pruritus (2.8%), rash (unspecified) (0.9%), and urticaria (0.9%). Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported with ivermectin use in postmarketing experience. Adverse reactions reported in 1% or less of patients treated with ivermectin topical lotion and/or cream in trials include xerosis, and skin burning sensation/skin irritation. Contact dermatitis and allergic dermatitis were reported in postmarketing use of ivermectin topical cream.
In patients being treated for onchocerciasis with ivermectin, adverse reactions related to allergic and inflammatory responses to the death of the microfilariae (the Mazzotti reaction) include fever (22.6%).
Adverse reactions associated with ivermectin used for strongyloidiasis treatment include asthenia/fatigue (0.9%).
Adverse reactions associated with ivermectin used for strongyloidiasis treatment include abdominal pain (0.9%), anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), and nausea (1.8%), vomiting (0.9%).
Adverse reactions associated with ivermectin used for strongyloidiasis treatment include dizziness (2.8%), drowsiness (0.9%), vertigo (0.9%), and tremor (0.9%). Seizures have been reported with ivermectin use in postmarketing experience.
Ophthalmological conditions (i.e., limbitis, punctate opacity) were examined in clinical trials involving adult onchocerciasis patients who received oral ivermectin. The ophthalmological changes observed were primarily deterioration from baseline 3 days post-treatment. Most changes returned to baseline or improved over baseline after 3 to 6 months. Significant adverse effects, such as visual impairment (e.g., loss of vision), do rarely occur and can occur with river blindness itself, but have also been reported with ivermectin therapy. These effects include abnormal sensation of the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. These effects generally resolve after treatment with corticosteroids. Conjunctival hemorrhage (ocular hemorrhage) has been reported with systemic ivermectin use for onchocerciasis in postmarketing experience. Adverse reactions reported in less than 1% of patients treated with ivermectin lotion include conjunctivitis, ocular hyperemia, and ocular irritation.
Orthostatic hypotension (1.1%) and sinus tachycardia (3.5%) have been reported with systemic ivermectin use.
Elevated hepatic enzymes have been reported in 2% of patients treated with systemic ivermectin. Hepatitis and hyperbilirubinemia have been reported postmarketing.
Ivermectin-associated neurotoxicity, including alteration or loss of consciousness (e.g., somnolence, drowsiness, stupor, coma), confusion, disorientation, and death have been reported in patients without onchocerciasis and in patients with onchocerciasis in the absence of Loa loa infection. These reactions have occurred after use of the recommended dosage and with overdosage of ivermectin and generally resolve with discontinuation of the drug and supportive care. Patients with onchocerciasis who are also heavily infected with Loa loa may develop a serious or even fatal encephalopathy, either spontaneously or after treatment with an effective microfilaricide. This syndrome has been seen very rarely after the use of ivermectin. These patients may also experience back pain, neck pain, red eye, conjunctival hemorrhage, dyspnea, urinary incontinence, fecal incontinence, difficulty in standing or walking, mental status changes, confusion, lethargy, stupor, seizures, or coma.
Although studies are conflicted, patients treated with ivermectin may have prolonged bleeding time due to a potential antagonistic effect with vitamin K. One study reported hematomatous swellings in 2 of 28 onchocerciasis patients treated with ivermectin, with prothrombin times significantly above baseline from one week to one month after treatment. An additional study showed prolonged prothrombin ratios in 148 patients given ivermectin. There were no reported bleeding complications; however, Factor II and VII levels were reduced in most patients with increased prothrombin times. In contrast, another study of 20 patients reported no changes in prothrombin times compared with baseline for 13 days after treatment. Bleeding disorders were also not found in 15,000 patients treated with ivermectin. Although there is no direct interaction with warfarin noted in the literature, coadministration of ivermectin and warfarin should be used with caution as there may be potentiation of prolonged prothrombin time. Post-marketing reports of increased INR have been rarely reported with the co-administration of ivermectin and warfarin. Patients with potential increased prothrombin times, such as those on warfarin, should use ivermectin with caution.
Decreased leukocyte count (3%), eosinophilia (3%), and increased hemoglobin (1%) have been reported with the use of systemic ivermectin. Leukopenia and and anemia were reported in one patients treated for strongyloidiasis.
Ivermectin is not an antiviral drug and is not FDA-approved for treating or preventing COVID-19. Off-label use of any drug can cause serious harm. Ivermectin intended for veterinary use in animals has not been evaluated for use in humans. Animal products are often highly concentrated and such high doses can be toxic in humans. Do not use veterinary ivermectin products as substitutes for FDA-approved human ivermectin products prescribed by a health care provider for appropriate indications.
Ivermectin is contraindicated in patients with hypersensitivity to any component of the product.
Patients with a history of severe asthma should receive ivermectin with caution. Occasionally, systemic ivermectin has been reported to worsen bronchial asthma.
Although not extensively studied, due to its extensive hepatic metabolism, ivermectin should be administered with caution in patients with significant hepatic disease.
In patients with immunosuppression (including those with human immunodeficiency virus (HIV) infection) treated for intestinal strongyloidiasis, repeated ivermectin courses may be necessary. Adequate and well-controlled clinical studies have not been conducted in such patients to determine the optimal dosing regimen. Several treatments (i.e., at 2 week intervals) may be required and a cure may not be achievable. Control of extra-intestinal strongyloidiasis in these patients is difficult, however, suppressive therapy (i.e., once per month) may be helpful.
Available data on the use of oral and topical ivermectin during pregnancy are insufficient to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal. Four published epidemiology studies evaluated the outcomes of a total of 744 patients exposed to oral ivermectin in various stages of pregnancy. In the largest study, 397 patients in the second trimester of pregnancy were treated open-label with single doses of ivermectin or ivermectin plus albendazole; there was no observed difference in pregnancy outcomes between treated and untreated populations. However, these studies cannot definitely establish or exclude the absence of drug-associated risk during pregnancy, because either the timing of the administration during gestation was not accurately ascertained or the administration only occurred during the second trimester. In animal embyrofetal development studies of oral ivermectin given during organogenesis, adverse developmental outcomes, including cleft palate, exencephaly, wavy ribs, and clubbed forepaws, occurred at or near doses that were maternally toxic. Pre-implantation loss and abortion were also noted.
After oral administration, ivermectin is excreted in human breast milk in low concentrations; however, there is insufficient information to determine the effects of ivermectin on the breast-fed infant or on milk production. According to the manufacturer, treatment with oral ivermectin in mothers who are breast-feeding should only be undertaken when the risk of delayed treatment to the mother outweighs the possible risk to the newborn. Previous American Academy of Pediatrics (AAP) recommendations considered oral ivermectin to be usually compatible with breast-feeding. The presence of ivermectin in human milk after topical application has not been studied; however, systemic exposure from topical ivermectin use is much lower than from oral use. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for topical ivermectin and any potential adverse effects on the breast-fed infant from exposure to the drug or from the underlying maternal condition. Women who are breast-feeding while using topical ivermectin should avoid accidental transfer of ivermectin to the breast area where it might be directly ingested while nursing.
The topical administration of ivermectin to infants and children should be under the direct supervision of an adult to prevent ingestion of the lotion.
Rarely, patients with onchocerciasis and Loa loa coinfection may develop a serious or even fatal encephalopathy either spontaneously or after treatment with an effective microfilaricide. This syndrome has been seen very rarely after the use of ivermectin. In individuals who warrant treatment with ivermectin for any reason and have had significant exposure to Loa loa-endemic areas of West and Central Africa, pretreatment assessment for loiasis and careful posttreatment follow-up is recommended.
Patients with hyperreactive onchodermatitis (i.e., sowda) may be more likely than others to experience severe edema and worsening of onchodermatitis after ivermectin use.
Per the manufacturer, this drug has been shown to be active against most strains of the following microorganisms either in vitro and/or in clinical infections: Onchocerca volvulus, Pediculus capitis, Strongyloides stercoralis
NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data only have not been established in adequate and well-controlled clinical trials.
This drug may also have activity against the following microorganisms: Pediculus corporis, Sarcoptes scabiei, Wuchereria bancrofti
NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, exclusion from this list does not necessarily negate the drug's activity against the organism.
For the treatment of onchocerciasis due to Onchocerca volvulus infection:
Adults, Adolescents, and Children >= 15 kg: Doses should be prescribed to provide approximately 150 mcg/kg PO as a single dose. Alternatively, the manufacturer recommends the following dose using 3 mg tablets based on patient weight: 1 tablet for patients weighing 15-25 kg; 2 tablets for patients weighing 26-44 kg; 3 tablets for patients weighing 45-64 kg; 4 tablets for patients weighing 65-84 kg; and 150 mcg/kg for patients weighing >= 85 kg. Repeated follow-up and retreatment is usually required because ivermectin does not kill the adult onchocerca parasites. Retreatment intervals may be as short as 3 months. NOTE: Surgical removal of the subcutaneous nodules in which the adult parasites reside may be considered to ensure elimination of the parasite. Corticosteriods, antihistamines, or other antiinflammatory agents (i.e., aspirin) may be prescribed concurrently in serious infections to reduce the likelihood of a Mazzotti reaction. Patients with Onchocerca volvulus infection who may also be infected with Loa loa, may develop a severe or fatal encephalopathy. Careful pre- and post-treatment assessments are recommended when administering ivermectin to patients from Loa loa-endemic areas of West or Central Africa.
Neonate, Infants, and Children < 15 kg: Safety and efficacy has not been established.
For the treatment of strongyloidiasis:
Adults weighing 80 kg or more: 200 mcg/kg/dose PO once daily for 1 to 2 days.
Adults weighing 66 to 79 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 15 mg.
Adults weighing 51 to 65 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 12 mg.
Adults weighing 36 to 50 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 9 mg.
Adolescents weighing 80 kg or more: 200 mcg/kg/dose PO once daily for 1 to 2 days.
Adolescents weighing 66 to 79 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 15 mg.
Children and Adolescents weighing 51 to 65 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 12 mg.
Children and Adolescents weighing 36 to 50 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 9 mg.
Children and Adolescents weighing 25 to 35 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 6 mg.
Children weighing 15 to 24 kg: 200 mcg/kg/dose once daily for 1 to 2 days. Usual dose: 3 mg.
For the treatment of scabies* infections, including crusted (Norwegian) scabies*:
-for the treatment of scabies*:
Adults: 200 mcg/kg/dose PO as a single dose, with a repeat dose 2 weeks later as a first line option. Ivermectin has been effective in the mass treatment of scabies in an institutionalized setting.
Topical dosage (lotion):
Adults: 1% lotion applied to all areas of the body from the neck down and washed off after 8 to 14 hours; repeat treatment in 1 week if symptoms persist.
-for the treatment of crusted scabies* (i.e., Norwegian scabies*) infection:
Adults: 200 mcg/kg/dose PO given as five doses (approximately days 1, 2, 8, 9, and 15), with consideration of two additional doses (approximately days 22 and 29) for severe infestations along with use of a topical scabicide (5% topical permethrin cream or 25% topical benzyl benzoate). Retreatment 2 weeks after the initial treatment regimen can be considered for those persons who are still symptomatic or when live mites are observed. Use of an alternative regimen is recommended for those persons who do not respond initially to the recommended treatment.
For the treatment of pediculosis including pediculosis capitis, pediculosis corporis*, and pediculosis pubis*:
-for the treatment of pediculosis capitis:
Topical dosage (lotion):
Adults: Apply a sufficient amount of lotion (up to 1 tube) to thoroughly coat dry hair and. Leave on for 10 minutes then rinse off with water. A fine-tooth comb or special nit comb may be used to remove dead lice and nits. Wait 24 hours before applying shampoo to hair and scalp after use.
Infants, Children, and Adolescents 6 months to 17 years: Apply a sufficient amount of lotion (up to 1 tube) to thoroughly coat dry hair and. Leave on for 10 minutes then rinse off with water. A fine-tooth comb or special nit comb may be used to remove dead lice and nits. Wait 24 hours before applying shampoo to hair and scalp after use.
Adults: 200 to 400 mcg/kg/dose PO for 2 doses, administered at least 7 days apart as an alternative.
Children and Adolescents weighing at least 15 kg: 200 to 400 mcg/kg/dose PO for 2 doses, administered at least 7 days apart as an alternative.
-for the treatment of pediculosis pubis*:
Adults: 250 mcg/kg/dose PO for 2 doses administered 7 to 14 days apart as an alternative.
-for the treatment of pediculosis corporis*:
Adults: 200 to 400 mcg/kg/dose PO for 2 doses, administered at least 7 days apart as an alternative. In one study, a 3 dose regimen was administered at 7-day intervals.
Children and Adolescents weighing at least 15 kg: 200 to 400 mcg/kg/dose PO for 2 doses, administered at least 7 days apart as an alternative. In one study, a 3 dose regimen was administered at 7-day intervals.
For the treatment of Bancroft's filariasis* caused by Wuchereria bancrofti*:
Adults and Children > 15 kg: 300 mcg/kg PO as a single dose or given annually for treatment in endemic areas.
For the secondary treatment of cutaneous larva currens* or cutaneous larva migrans*:
Adults and Children > 15 kg: 150 mcg/kg PO as a single dose. A second and occasionally a third dose of ivermectin, each dose one week apart, is necessary if pruritis persists or if the larva continues to migrate 1 week after the previous dose.
For the treatment of inflammatory lesions of acne rosacea:
Topical dosage (cream):
Adults: Apply a pea-sized amount as a thin layer to the affected area(s) of the face (e.g., forehead, chin, nose, and each cheek) once daily.
For the treatment of ascariasis (roundworm infection)*:
Adults: 150 to 200 mcg/kg/dose PO as a single dose.
Children and Adolescents weighing 15 kg or more: 150 to 200 mcg/kg/dose PO as a single dose.
For the treatment of enterobiasis (pinworm infection)*:
Adults: 200 mcg/kg/dose PO as a single dose; repeat dose in 2 weeks.
Children and Adolescents weighing 15 kg or more: 200 mcg/kg/dose PO as a single dose; repeat dose in 2 weeks.
For the treatment of trichuriasis (whipworm infection)*:
Adults: 200 mcg/kg/dose PO once daily for 3 days.
Children and Adolescents weighing 15 kg or more: 200 mcg/kg/dose PO once daily for 3 days.
Maximum Dosage Limits:
150-200 mcg/kg single dose PO for most indications; up to 400 mcg/kg PO for Bancroft's filariasis; 4 oz/topical application.
150-200 mcg/kg single dose PO for most indications; 4 oz/topical application.
150-200 mcg/kg single dose PO for most indications; 4 oz/topical application.
> 15 kg: 150-200 mcg/kg single dose PO for most indications; 4 oz/topical application.
<= 15 kg: Safety and efficacy have not been established for oral dosage forms; 4 oz/topical application.
>= 6 months: Safety and efficacy have not been established for oral dosage forms; 4 oz/topical application.
< 6 months: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
Patients with abnormal liver tests prior to beginning ivermectin therapy should be carefully evaluated.
Patients with Renal Impairment Dosing
The pharmacokinetics of ivermectin in patients with renal impairment has not been studied; however, renal elimination of this drug is negligible and dosage adjustment in renal impairment is not expected to be necessary.
Aprepitant, Fosaprepitant: (Moderate) Use caution if ivermectin and aprepitant, fosaprepitant are used concurrently and monitor for an increase in ivermectin-related adverse effects for several days after administration of a multi-day aprepitant regimen. Ivermectin is a CYP3A4 substrate. Aprepitant, when administered as a 3-day oral regimen (125 mg/80 mg/80 mg), is a moderate CYP3A4 inhibitor and inducer and may increase plasma concentrations of ivermectin. For example, a 5-day oral aprepitant regimen increased the AUC of another CYP3A4 substrate, midazolam (single dose), by 2.3-fold on day 1 and by 3.3-fold on day 5. After a 3-day oral aprepitant regimen, the AUC of midazolam (given on days 1, 4, 8, and 15) increased by 25% on day 4, and then decreased by 19% and 4% on days 8 and 15, respectively. As a single 125 mg or 40 mg oral dose, the inhibitory effect of aprepitant on CYP3A4 is weak, with the AUC of midazolam increased by 1.5-fold and 1.2-fold, respectively. After administration, fosaprepitant is rapidly converted to aprepitant and shares many of the same drug interactions. However, as a single 150 mg intravenous dose, fosaprepitant only weakly inhibits CYP3A4 for a duration of 2 days; there is no evidence of CYP3A4 induction. Fosaprepitant 150 mg IV as a single dose increased the AUC of midazolam (given on days 1 and 4) by approximately 1.8-fold on day 1; there was no effect on day 4. Less than a 2-fold increase in the midazolam AUC is not considered clinically important.
Idelalisib: (Major) Avoid concomitant use of idelalisib, a strong CYP3A inhibitor, with ivermectin, a CYP3A substrate, as ivermectin toxicities may be significantly increased. The AUC of a sensitive CYP3A substrate was increased 5.4-fold when coadministered with idelalisib.
Mirabegron: (Moderate) Mirabegron is a moderate CYP2D6 inhibitor. Exposure of drugs metabolized by CYP2D6 such as ivermectin may be increased when co-administered with mirabegron. Ivermectin has been shown to be a CYP2D6 substrate in vitro. Appropriate monitoring and dose adjustment may be necessary.
Mitotane: (Moderate) Use caution if mitotane and ivermectin are used concomitantly, and monitor for decreased efficacy of ivermectin and a possible change in dosage requirements. Mitotane is a strong CYP3A4 inducer and ivermectin is a CYP3A4 substrate. Coadministration may result in decreased plasma concentrations of ivermectin; however, ivermectin is administered as a single dose, and significant clinical interactions are not expected.
Posaconazole: (Moderate) Posaconazole and ivermectin should be coadministered with caution due to an increased potential for ivermectin-related adverse events. Posaconazole is a potent inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of ivermectin. These drugs used in combination may result in elevated ivermectin plasma concentrations, causing an increased risk for ivermectin-related adverse events.
Warfarin: (Moderate) Concurrent administration of warfarin and oral ivermectin has been associated with postmarketing reports of elevated INR. In 1 case report, a patient who was previously stable on warfarin developed supratherapeutic INR concentrations (greater than 20) and subsequent hematoma after receiving two 3 mg oral ivermectin doses. Although data are limited, ivermectin has been shown to antagonize vitamin K-dependent clotting factors II, VII, IX, and X.
Avermectins, including ivermectin, are broad-spectrum antiparasitic agents. They bind selectively and with high affinity to glutamate-gated chloride ion channels present in invertebrate nerve and muscle cells. This binding leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. This class of compounds may also bind with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA). The avermectins' selectivity is due to the fact that some mammals do not have glutamate-gated chloride channels and that the avermectins have a low affinity for mammalian ligand-gated chloride channels. Ivermectin does not cross the blood-brain barrier in humans.
Ivermectin is administered orally and topically.
Affected cytochrome P450 isoenzymes: CYP3A4, CYP2D6, CYP2E1
Ivermectin is hepatically metabolized. It is primarily metabolized by cytochrome P450 3A4, and theoretically the metabolism may be affected by inducers and inhibitors of this enzyme. However, ivermectin is administered as a single dose, and significant clinical interactions are not expected. Depending on the in vitro method used, the CYP2D6 and CYP2E1 isoenzymes may also be involved in metabolism but to a significantly lower extent than CYP3A4. In vitro studies using human liver microsomes suggest that ivermectin does not significantly inhibit the CYP3A4, CYP2D6, CYP2C9, CYP1A2, or CYP2E1 isoenzymes.
Ivermectin and its inactive metabolites are excreted almost exclusively in the feces over 12 days. Less than 1% of the dose is excreted in the urine. The plasma half life is reported as 16 to 28 hours, the volume of distribution is 46.9 L, and clearance is 1.2 L/h after oral administration.
Following oral administration, ivermectin is well absorbed with plasma concentrations proportional to the dose. The effect of food on the absorption of ivermectin has not been determined, therefore the drug is recommended to be taken on an empty stomach with water.
After a single application of ivermectin lotion, systemic concentrations are much lower than those observed after oral administration of ivermectin at a dose of 165 mcg/kg PO. The mean Cmax and AUC from time zero to the time of last measurable concentration were 0.24 +/- 0.23 ng/mL and 6.7 +/- 11.2 hour x ng/mL, respectively.
After 2 weeks of treatment with ivermectin cream, the Tmax was 10 +/- 8 hours, the Cmax was 2.1 +/- 1.04 ng/mL and AUC was 36.15 +/- 15.56 ng x hour/mL. At the end of the 52-week treatment period, there was no plasma accumulation of ivermectin. The terminal half-life was 6.5 days (155 +/- 40 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days.
Although not extensively studied, ivermectin plasma concentrations can be expected to increase significantly in patients with hepatic disease.
Since renal elimination of ivermectin is minimal, it is unlikely that renal impairment alters the clearance of this drug.
Limited data suggest similar pharmacokinetics in children > 15 kg as compared to younger adults with weight-based dosing. Ivermectin pharmacokinetic data after systemic administration are not available for children < 15 kg. The pharmacokinetics of topical ivermectin were studied in 20 infants and children ages 6 months to 3 years; very low systemic exposure resulted from topical administration for the treatment of lice.
Limited data suggests similar ivermectin pharmacokinetics in the elderly as compared to younger adults with weight-based dosing.